• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ocugen, Inc. - Common Stock (NQ:OCGN)

1.460 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ocugen, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
36 37 Next >
News headline image
Ocugen, Inc. Announces Closing for $130.0 Million of 6.75% Convertible Senior Notes
May 14, 2026
Includes Full Exercise of $15.0 million Over-Allotment Option 
From Ocugen
Via GlobeNewswire
News headline image
3 Reasons Not to Buy Into the Hantavirus-Related Biotech Rally ↗
May 13, 2026
Investors can find much better opportunities. 
Via The Motley Fool
News headline image
Ocugen to Participate in Upcoming May Scientific and Investor Conferences
May 13, 2026
From Ocugen
Via GlobeNewswire
Ocugen (NASDAQ:OCGN) Beats Q1 Revenue Estimates but Widens Net Loss, Announces $115M Capital Raise to Fund Pipeline Through 2028 ↗
May 05, 2026
Via Chartmill
Ocugen Inc (NASDAQ:OCGN) Stock Drops 7% on Q4 Revenue Miss, Highlights Clinical Pipeline ↗
March 04, 2026
Via Chartmill
News headline image
Ocugen Provides Business Update with First Quarter 2026 Financial Results
May 05, 2026
From Ocugen
Via GlobeNewswire
News headline image
Ocugen, Inc. Announces Pricing of $115 Million of 6.75% Convertible Senior Notes
May 05, 2026
From Ocugen
Via GlobeNewswire
Top movers in Monday's after hours session ↗
May 04, 2026
Via Chartmill
News headline image
Ocugen Announces Private Offering of $115 Million of Convertible Senior Notes
May 04, 2026
From Ocugen
Via GlobeNewswire
News headline image
Ocugen to Host Conference Call on Tuesday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2026 Financial Results
April 29, 2026
From Ocugen
Via GlobeNewswire
News headline image
Ocugen to Present at April 2026 Investor and Industry Conferences
April 23, 2026
From Ocugen
Via GlobeNewswire
News headline image
Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease
April 01, 2026
From Ocugen
Via GlobeNewswire
News headline image
Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
March 24, 2026
From Ocugen
Via GlobeNewswire
News headline image
Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410—Modifier Gene Therapy for Geographic Atrophy
March 23, 2026
From Ocugen
Via GlobeNewswire
News headline image
OCGN Stock Rallies On Wall Street Optimism For Clinical Pipeline: Retail Awaits New Data ↗
March 17, 2026
Canaccord has a $12 price target on the stock, representing a potential upside of about 415% from the stock’s closing price on Monday. 
Via Stocktwits
Keep an eye on the top gainers and losers in Wednesday's session. ↗
March 11, 2026
Via Chartmill
Top movers in Wednesday's session ↗
March 11, 2026
Via Chartmill
News headline image
Ocugen (OCGN) Q4 2025 Earnings Call Transcript ↗
March 04, 2026
Ocugen (OCGN) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results
March 04, 2026
Conference Call and Webcast Today at 8:30 a.m. ET 
From Ocugen
Via GlobeNewswire
News headline image
Investors Eye Explosive Growth in Anti-Aging Therapies as Market Targets $420B Milestone
March 03, 2026
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:GERN),(NASDAQ:NTLA),(NASDAQ:NAGE),(NASDAQ:OCGN) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa
March 02, 2026
From Ocugen
Via GlobeNewswire
News headline image
Why Did OCGN Stock Rise Today? ↗
February 25, 2026
Ocugen said that it intends to start seeking the approval of the FDA for its experimental therapy OCU400 starting this year. 
Via Stocktwits
News headline image
Ocugen to Host Conference Call on Wednesday, March 4, 2026 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2025 Financial Results
February 18, 2026
From Ocugen
Via GlobeNewswire
News headline image
Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer
February 09, 2026
From Ocugen
Via GlobeNewswire
News headline image
Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock
January 23, 2026
From Ocugen
Via GlobeNewswire
News headline image
Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock
January 21, 2026
From Ocugen
Via GlobeNewswire
News headline image
Ocugen Stock Is Surging Today: What&#39;s Driving The Action? ↗
January 16, 2026
Ocugen Inc (NASDAQ:OCGN) shares are up on Friday as the company is gaining traction following positive market sentiment. 
Via Benzinga
News headline image
Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
January 15, 2026
From Ocugen
Via GlobeNewswire
News headline image
Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data
January 13, 2026
From Ocugen
Via GlobeNewswire
News headline image
OCGN Stock Rises Pre-Market After Gene Therapy Data Shows Promise In Rare Eye Disorder ↗
January 12, 2026
Stargardt disease is a form of inherited macular degeneration, affecting more than 100,000 people in the U.S. and Europe combined. 
Via Stocktwits
< Previous 1 2 3 4 5 6 7 8 9
...
36 37 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap